Analysts at GlobalData have previously forecast that Spravato will generate global sales of approximately $383 million by 2029, with its potential pegged back by its cost and a requirement for two ...

The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers. “A lot of people didn’t think it would work ...

It is a legal medical treatment. The 34-year-old doctor from Denver is taking Spravato, a medicine derived from club-drug ...

Prescriptions for Spravato, which is psychedelic-based drug made by Johnson & Johnson, are booming and new clinics are opening that specialize in administering it, Peter Loftus of The Wall Street ...